COMPASS Pathways synthesizes 20,000 doses of psilocybin for use in clinical trials.
COMPASS Pathways creates 20,000 doses of synthetic psilocybin for use in clinical trials. Their current research focus is on treating patients with treatment-resistant depression.
Psychedelic Science Review is working to bring cutting-edge science in the field of psychedelics to the public in the most accessible, thorough and accurate way possible. Join our communities on Facebook, Twitter, LinkedIn and Instagram and share our content with your network to help us bring scientifically-backed information about psychedelics to the world.
NEW! Shop the PSR Supporter Store to show your support for psychedelic science.